Bausch & Lomb Corp (BLCO) stock intrinsic value fair value estimate & owner earnings analysis

Bausch + Lomb is one of the oldest names in eye care. It sells contact lenses (Biotrue, ULTRA, INFUSE) and lens-care solutions, consumer eye products (PreserVision eye vitamins, Lumify redness drops, artificial tears), surgical equipment and implants for cataract and retina surgery (including enVista intraocular lenses), and prescription eye drugs (Xiidra and Miebo for dry eye, Lotemax, Vyzulta). 2025 revenue was $5.1 billion, about half from the United States and Puerto Rico. Bausch Health owns about 88% of the shares and has said it still believes separating from the company makes sense, whether by selling it or by distributing the shares to its own shareholders; that ownership decides the company's direction, and nothing about a possible sale is counted in the value below. How we measured earnings. We start from operating cash flow, strip out working-capital swings, and subtract stock-based pay (a real cost: $149 million in 2025) and the capital spending needed to keep the business running. Amortization of acquired products, such as the roughly $1.75 billion Xiidra purchase in 2023, is added back because it is a non-cash charge, so the fading value of those products is handled in the forecasts instead. Because the company carries heavy debt, we value the business before interest and then subtract what it owes. On that basis, before interest, the business generated about $259 million in 2022, $275 million in 2023, $388 million in 2024 (the first full year with Xiidra) and $165 million in 2025. The 2025 figure was held down by the March 2025 recall of enVista lenses (sales were back to pre-recall levels in the fourth quarter), higher tariffs and much higher stock-based pay. The first half of 2026 was much stronger: operating cash flow was $185 million, against $10 million a year earlier. GAAP results tell the same story. The company lost $360 million in 2025. Adding back the roughly $380 million of interest paid and about $260 million of acquired-product amortization leaves roughly $250-300 million. On $5 billion of revenue, that is a thin return for the owners. What it owes. At June 30, 2026 the company had about $5.13 billion of borrowings against $367 million of cash, plus a small minority interest in a subsidiary. The debt costs about 7.7% on average: $1.4 billion of 8.375% notes and a $489 million term loan both mature in 2028, and a $2.3 billion term loan and €675 million of floating-rate notes mature in January 2031. The 2025 refinancing was done at about 8%, so we expect borrowing to stay expensive. We treat the cost above a normal 6% rate as extra debt, about $0.39 billion in the base case. Borrowings rose from $4.56 billion at the end of 2023 to over $5.0 billion even without a large acquisition, because after stock pay and capital spending the business has produced less cash than its roughly $390 million a year interest bill. Base case (about -$0.16 per share). Pre-interest cash flow of about $360 million in the coming year as the recall recovery seen since late 2025 holds, then about $340 million a year for ten years. Tariffs and generic erosion eat into that: the PreserVision patent expired in early 2026 (about 6% of sales), and a settlement allows a generic Lumify from June 30, 2027. No growth is credited. Reported revenue grew 6.5% in 2025 and about 9% in the first half of 2026, but that came from market growth, share gains and new launches, which we do not count as secured. After ten years, Xiidra and Miebo face their own patent expiries. The contact-lens, lens-care and surgical-consumable franchises, which customers rebuy constantly, together with the company's long record of licensing or buying replacement eye drugs (Lumify, Vyzulta, Miebo, Xiidra), support about $300 million a year from then on. The business is worth about $5.31 billion and owes about $5.37 billion, so the shares are worth roughly nothing. Bear case (about -$6.09 per share). Recent cash flow falls back to the weaker years, about $270 million and then $230 million a year, as tariffs, pricing pressure and generic PreserVision and Lumify bite. The 2028 maturities are refinanced at higher rates, and after year ten the drug exclusivities lapse with little replacement, leaving about $180 million a year. The business is worth about $3.41 billion against about $5.58 billion owed. In this case the company owes roughly $2.2 billion more than it is worth. Bull case (about $5.83 per share). The post-recall run rate holds at about $430 million and then $470 million a year. Capital spending, which ran $175-193 million a year in 2021-2023 and has already fallen in the first half of 2026, eases back from its 2025 peak of $349 million, and the replacement of maturing drugs keeps working, supporting about $420 million a year after year ten. The business is worth about $7.33 billion against about $5.25 billion owed, leaving about $2.08 billion for shareholders. The biggest judgment is capital spending. Capex of $349 million in 2025 was more than twice depreciation of $163 million. Some of that may be expansion, but we count most of it as upkeep because revenue grew only modestly. If maintenance spending is really closer to depreciation, the business earns about $170 million a year more, which would add roughly $7-8 per share to the base case. That is the main thing that would prove this valuation too low. It would be too high if the recent recovery fades or the 2028 refinancing costs more. With the equity squeezed between a thin cash margin and $5 billion of 7-8% debt, the margin-of-safety price sits well below the bull value, and the business has yet to show it can cover its interest from its own cash.